Shopping Cart
- Remove All
- Your shopping cart is currently empty
CU-CPT17e is a potent agonist of TLR(TLR3, TLR8, and TLR9).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $213 | In Stock | |
5 mg | $441 | In Stock | |
10 mg | $649 | In Stock | |
25 mg | $987 | In Stock | |
50 mg | $1,390 | In Stock | |
100 mg | $1,870 | In Stock |
Description | CU-CPT17e is a potent agonist of TLR(TLR3, TLR8, and TLR9). |
In vitro | The first small molecule 17e (CU-CPT17e) capable of simultaneously activating TLRs 3, 8, and 9. Biochemical studies demonstrated that 17e could induce a strong immune response via the production of various cytokines in human monocytic THP-1 cells. Furthermore, 17e inhibited the proliferation of HeLa cancer cells by triggering apoptosis and arresting the cell cycle at the S phase. These results showcase potential therapeutic applications of 17e in both vaccine adjuvants and anticancer therapies based on multi-TLR activation. |
Molecular Weight | 504.49 |
Formula | C27H24N2O8 |
Cas No. | 2109805-75-4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||
Solubility Information | DMSO: 2 mg/mL (3.96 mM), Sonication is recommended. | ||||||||||
Solution Preparation Table | |||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.